Skip to content

Erenumab

NERVOUS SYSTEM

Also known as: aimovig, AMG 334, AMG-334, erenumab (genetical recombination), erenumab-aooe

EMA approvedFDA approvedPMDA approvedATC N02CD01

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Erenumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 1 molecular target, including RAMP1|CALCRL. Recorded indications include Migraine and Prevention of migraine attacks.

  • Molecular targets: RAMP1|CALCRL (1 listed in DrugCentral).
  • Indications: Migraine and Prevention of migraine attacks.
  • ATC code: N02CD01 (Calcitonin gene-related peptide (CGRP) antagonists).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Migraine
  • Prevention of migraine attacks

Mechanism & targets

Molecular targets (1)

TargetGeneActionActivity
Calcitonin-gene-related peptide receptorRAMP1|CALCRLotherKi 10.70

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2021-06-23PMDA—AMGEN K.K.
2018-07-26EMA—NOVARTIS EUROPHARM LIMITED
2018-05-17FDA—AMGEN INC

ATC classification

ATC codeTherapeutic hierarchy
N02CD01NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Accidental exposure to product14840.6
Wrong technique in product usage process12302.6
Device difficult to use11915.9
Drug dose omission by device5791.2
Product storage error3401.1
Intercepted product administration error1998.8
Device issue1919.2
Incorrect dose administered by device1601.4
Blepharospasm1341.6
Occupational exposure to product1328.1
Device use error1292.9
Injection site haemorrhage1136.9

Chemical structure

Molecular formula—
Molecular weight—
CAS number1582205-90-0
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Erenumab used for?

DrugCentral lists the following indications for Erenumab: Migraine and Prevention of migraine attacks.

How does Erenumab work?

Its molecular targets in DrugCentral include RAMP1|CALCRL.

When was Erenumab first approved?

Erenumab was first approved by the FDA in 2018.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2018-05-17
AgencyFDA
Targets1
Indications2
Formula—
DrugCentral ID5284
Interactive profile